BioStock: Targinta’s new CEO has started

On September 1, Per Norlén took on the role of CEO of Targinta, Xintela's oncology subsidiary, which is being prepared to be spun off from Xintela in 2021. Norlén plans to develop Targinta to become an independent and self-funded cancer company, which he talks more about in an interview with BioStock.

Read the full interview with Targinta's CEO Per Norlén at biostock.se:

https://www.biostock.se/en/2021/09/targintas-new-ceo-has-started/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/